Floatz logo

CM-101 CCL24 BLOCKING MONOCLONAL ANTIBODY

Systemic Sclerosis

ChemomAb Ltd.monoclonal_antibodyPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

25 Active assets in the Systemic Sclerosis cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Royal Brompton & Harefield NHS Foundation Trust
Phase 2/3BB
Iloprost
National Center for Research Resources (NCRR)
Phase 3BB
Bosentan
Actelion
Phase 3B
Rituximab
Royal Brompton & Harefield NHS Foundation Trust
Phase 2/3B
ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN, RABBIT
Fred Hutchinson Cancer Center
Phase 2B

View all 41 →

Same molecule, other indications

CM-101 CCL24 BLOCKING MONOCLONAL ANTIBODY is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative · Phase 2
64 / 100
View asset →
primary sclerosing cholangitisDormant
B
Indicative · Phase 2
61 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
CC
Indicative · Phase 1
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →